HEMATOLOGICAL MALIGNANCIES
Clinical trials for HEMATOLOGICAL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New smart drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis trial tests a new drug called DS3790a for people with certain blood cancers, including B-cell non-Hodgkin lymphoma. The drug is designed to find and attack cancer cells while sparing healthy ones. The study will check safety and how well it works in about 420 adults.
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug shows promise for Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new drug called talquetamab in people with multiple myeloma that has come back or stopped responding to treatment. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to find the best dose and see how well…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug cocktail aims to stop transplant rejection in blood cancer patients
Disease control Recruiting nowThis study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and abatacept) can prevent graft-versus-host disease (GvHD) in people receiving a stem cell transplant for blood cancers. About 74 adults will take part. The goal is to reduce severe immune react…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a lower drug dose improve life after stem cell transplant for older adults?
Disease control Recruiting nowThis study is for adults aged 60 and older with blood cancers who need a stem cell transplant. It compares a standard high dose of a drug (cyclophosphamide) with a lower dose, both combined with another drug (sirolimus), to prevent graft-versus-host disease (GVHD). The goal is to…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New study maps best antibiotic steps for fever in cancer patients
Disease control Recruiting nowThis study tests a specific order of antibiotics for cancer patients who develop fever due to low white blood cells (febrile neutropenia). Twenty adults with blood cancers will receive a carbapenem first, then add vancomycin or linezolid if fever persists, and finally an antifung…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Sponsor: Shanxi Bethune Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill HMPL-506 enters human testing for Hard-to-Treat leukemias
Disease control Recruiting nowThis early study tests an experimental oral drug called HMPL-506 in about 132 adults with specific types of leukemia (AML or ALL) that have come back or not responded to treatment. The main goal is to check safety and find the right dose. Researchers will also look for signs that…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill shows promise against blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests an experimental drug called ICP-248, taken as a pill, for people with certain blood cancers (like leukemia or lymphoma). The drug is given alone or with another drug, orelabrutinib. The main goals are to check safety, find the right dose, and see if i…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:15 UTC
-
Nurse chats could ease cancer kids' suffering
Symptom relief Recruiting nowThis study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
15-Year watch begins for CAR T-Cell therapy recipients
Knowledge-focused Recruiting nowThis study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will check for long-term side effects and how well the treatment works over 15 years. No new treatment is given—just regular monitoring to meet safety guide…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE3 • Sponsor: Lakefront Biotherapeutics NV • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive study aims to unlock secrets of early blood cancers
Knowledge-focused Recruiting nowThis study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC